1Department of Gastroenterology, Flinders Medical Centre, Flinders University, Adelaide, Australia
2Stratos Technology Partners, Christchurch, New Zealand
3IBD Service, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia
4Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK
5Crohn’s Colitis Cure, Sydney, Australia
6Department of Gastroenterology, Liverpool Hospital, University of NSW and Ingham Institute of Applied Medical Research, Liverpool, Australia
7School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, Australia
© Copyright 2022. Korean Association for the Study of Intestinal Diseases.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Funding Source
This work was supported in part by a research grant from the Investigator-Initiated Studies Program of Organon (grant number: MSD IIS 55839). The opinions expressed in this paper are those of the authors and do not necessarily represent those of Organon.
Conflict of Interest
Andrews JM has been on advisory boards, been a speaker and received research and/or educational support from AbbVie, Allergan, Anatara, Bayer, Celgene, Celltrion, Ferring, Gilead, Hospira, Immunic, Janssen, MSD, Nestle, Pfizer, Sandoz, Shire, Takeda, Vifor, Novartis. Connor S has been on advisory boards, been a speaker and received research and/or educational support from AbbVie, Janssen, Pfizer, Shire, Takeda, Ferring, MSD, Vifor, Celgene, Orphan, Gilead, Celltrion, Aspen. Other authors report no conflict of interest.
Data Availability Statement
The data used in this work was generated as part of routine care at the Royal Adelaide Hospital and Liverpool Hospital. The data underlying this article will be shared on reasonable request to the corresponding author.
Author Contribution
Conceptualization: Barnes A, Walsh A, Connor S, Andrews JM. Data curation: Barnes A, Carter D, Kaazan P. Formal analysis: Barnes A. Methodology: Barnes A. Writing-original draft: Barnes A, Andrews JM. Writing - review & editing: Barnes A, Walsh A, Connor S, Andrews JM. Approval of final manuscript: all authors.
Others
The data used in this work was generated as part of routine care at the Royal Adelaide Hospital and Liverpool Hospital. The data underlying this article will be shared on reasonable request to the corresponding author.
Medication at time of clinical assessment (No. clinical assessments) | Active disease (%) |
---|---|
Biologic (n = 1,968) | 28.7 |
Monotherapy (n = 1,150) | 28.2 |
With immunomodulator (n = 818) | 29.4 |
Anti-TNF-α (n = 1,394)a | 26.2 |
Other biologics (n = 574)b | 35.0 |
Immunomodulator (n = 1,394) | 37.5 |
Not on biologic (n = 576) | 43.4 |
5-ASA (n = 2,122)c | 42.5 |
Medication at time of clinical assessment (No. clinical assessments) | Active disease (%) |
---|---|
Biologic (n = 1,968) | 28.7 |
Monotherapy (n = 1,150) | 28.2 |
With immunomodulator (n = 818) | 29.4 |
Anti-TNF-α (n = 1,394) |
26.2 |
Other biologics (n = 574) |
35.0 |
Immunomodulator (n = 1,394) | 37.5 |
Not on biologic (n = 576) | 43.4 |
5-ASA (n = 2,122) |
42.5 |
Anti-tumor necrosis factor α (TNF-α) antibodies such as infliximab, adalimumab, or golimumab. Other biologics include vedolizumab, ustekinumab, and tofacitinib. 5-Aminosalicylic acids (5-ASAs) such as mesalazine or sulfasalazine.